Clinical Report: Evaluating Cystatin C as a Diagnostic Marker for AKI in Sepsis
Overview
This systematic review and meta-analysis evaluates the diagnostic performance of cystatin C (CysC) for early detection of acute kidney injury (AKI) in sepsis patients. The findings indicate that CysC has good diagnostic accuracy, with an area under the curve (AUC) of 0.88, sensitivity of 0.81, and specificity of 0.82.
Background
Acute kidney injury (AKI) is a critical condition that can lead to severe complications and high mortality rates, particularly in sepsis patients. The timely diagnosis of sepsis-associated acute kidney injury (SA-AKI) is essential for improving patient outcomes. Traditional markers like serum creatinine have limitations in early detection, highlighting the need for more reliable biomarkers such as cystatin C.
Data Highlights
Metric
Value
AUC
0.88
Sensitivity
0.81
Specificity
0.82
Key Findings
Cystatin C shows good diagnostic performance for SA-AKI.
The AUC for cystatin C is 0.88, indicating strong diagnostic accuracy.
Sensitivity and specificity of cystatin C are 0.81 and 0.82, respectively.
Subgroup analyses indicate higher specificity and diagnostic odds ratio in studies using Sepsis 3.0 criteria.
Combining cystatin C with other biomarkers improves diagnostic accuracy.
Clinical Implications
Cystatin C may serve as a valuable biomarker for the early diagnosis of SA-AKI, potentially allowing for timely interventions. Clinicians should consider its use alongside traditional markers to enhance diagnostic accuracy in critically ill patients.
Conclusion
The findings support the potential role of cystatin C in the early diagnosis of SA-AKI, although further research is needed to address the heterogeneity among studies.
